Literature DB >> 25447133

Histopathology of MPGN and C3 glomerulopathies.

H Terence Cook1, Matthew C Pickering1.   

Abstract

'Membranoproliferative' describes glomerular injury characterized by capillary wall thickening and mesangial expansion owing to increased matrix deposition and hypercellularity. The presence of immune deposits is indicative of membranoproliferative glomerulonephritis (MPGN). Historically, MPGN was further classified into three types according to the appearance and site of the electron-dense deposits seen by electron microscopy, but it is now recognized that many cases show only deposition of the complement component C3, owing to abnormal control of the alternative pathway of complement activation-these cases are now classified as C3 glomerulopathies. Not all cases of C3 glomerulopathy, however, show an MPGN pattern. C3 glomerulopathies include dense deposit disease, which shows dense osmiophilic deposits, and C3 glomerulonephritis, which shows isolated deposits. In many cases, the genetic mutations or autoantibodies responsible for C3 deposition have been identified. Some patients in whom complement control is abnormal will accumulate small amounts of immunoglobulin in their glomeruli and so, in everyday practice, the morphological diagnosis of 'glomerulonephritis with dominant C3' is useful for identifying patients who require investigation of the complement pathway. The recognition that many cases of MPGN are C3 glomerulopathies and that the underlying cause can often be identified in immunoglobulin-associated cases means that the diagnosis of idiopathic MPGN is now very uncommon.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25447133     DOI: 10.1038/nrneph.2014.217

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  57 in total

1.  Dense deposit disease: a variant of membranoproliferative glomerulonephritis.

Authors:  R Habib; M C Gubler; C Loirat; H B Mäiz; M Levy
Journal:  Kidney Int       Date:  1975-04       Impact factor: 10.612

2.  C3 glomerulopathy: clinicopathologic features and predictors of outcome.

Authors:  Nicholas R Medjeral-Thomas; Michelle M O'Shaughnessy; John A O'Regan; Carol Traynor; Michael Flanagan; Limy Wong; Chia Wei Teoh; Atif Awan; Mary Waldron; Tom Cairns; Patrick O'Kelly; Anthony M Dorman; Matthew C Pickering; Peter J Conlon; H Terence Cook
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

3.  Allelic variants of complement genes associated with dense deposit disease.

Authors:  Maria Asuncion Abrera-Abeleda; Carla Nishimura; Kathy Frees; Michael Jones; Tara Maga; Louis M Katz; Yuzhou Zhang; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 10.121

4.  Glomerulonephritis with basement membrane dense deposits.

Authors:  E H Jenis; P Sandler; G S Hill; M R Knieser; G E Jensen; S D Roskes
Journal:  Arch Pathol       Date:  1974-02

5.  Causes of alternative pathway dysregulation in dense deposit disease.

Authors:  Yuzhou Zhang; Nicole C Meyer; Kai Wang; Carla Nishimura; Kathy Frees; Michael Jones; Louis M Katz; Sanjeev Sethi; Richard J H Smith
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-05       Impact factor: 8.237

6.  Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H.

Authors:  T S Jokiranta; A Solomon; M K Pangburn; P F Zipfel; S Meri
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

7.  Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II).

Authors:  C Licht; S Heinen; M Józsi; I Löschmann; R E Saunders; S J Perkins; R Waldherr; C Skerka; M Kirschfink; B Hoppe; P F Zipfel
Journal:  Kidney Int       Date:  2006-04-12       Impact factor: 10.612

8.  C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.

Authors:  Agustín Tortajada; Hugo Yébenes; Cynthia Abarrategui-Garrido; Jaouad Anter; Jesús M García-Fernández; Rubén Martínez-Barricarte; María Alba-Domínguez; Talat H Malik; Rafael Bedoya; Rocío Cabrera Pérez; Margarita López Trascasa; Matthew C Pickering; Claire L Harris; Pilar Sánchez-Corral; Oscar Llorca; Santiago Rodríguez de Córdoba
Journal:  J Clin Invest       Date:  2013-06       Impact factor: 14.808

Review 9.  Hypothesis: dysregulation of immunologic balance resulting from hygiene and socioeconomic factors may influence the epidemiology and cause of glomerulonephritis worldwide.

Authors:  Richard J Johnson; Abdias Hurtado; Justin Merszei; Bernardo Rodriguez-Iturbe; Lili Feng
Journal:  Am J Kidney Dis       Date:  2003-09       Impact factor: 8.860

10.  Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement.

Authors:  Sanjeev Sethi; Fernando C Fervenza; Yuzhou Zhang; Ladan Zand; Nicole C Meyer; Nicolò Borsa; Samih H Nasr; Richard J H Smith
Journal:  Kidney Int       Date:  2012-12-12       Impact factor: 10.612

View more
  43 in total

Review 1.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

Review 2.  C3 Glomerulopathy.

Authors:  Magdalena Riedl; Paul Thorner; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

3.  Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.

Authors:  Johannes Holle; Lena Berenberg-Goßler; Kaiyin Wu; Ortraud Beringer; Florian Kropp; Dominik Müller; Julia Thumfart
Journal:  Pediatr Nephrol       Date:  2018-09-20       Impact factor: 3.714

Review 4.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

Review 5.  Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2016-07-06

6.  Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.

Authors:  Maria Chiara Marinozzi; Lubka T Roumenina; Sophie Chauvet; Alexandre Hertig; Dominique Bertrand; Jérome Olagne; Marie Frimat; Tim Ulinski; Georges Deschênes; Stephane Burtey; Michel Delahousse; Bruno Moulin; Christophe Legendre; Véronique Frémeaux-Bacchi; Moglie Le Quintrec
Journal:  J Am Soc Nephrol       Date:  2017-01-17       Impact factor: 10.121

Review 7.  Precision Transplant Medicine: Biomarkers to the Rescue.

Authors:  Maarten Naesens; Dany Anglicheau
Journal:  J Am Soc Nephrol       Date:  2017-10-09       Impact factor: 10.121

Review 8.  [Membranoproliferative glomerulonephritis and C3 glomerulopathy].

Authors:  B Hohenstein; K Amann; J Menne
Journal:  Internist (Berl)       Date:  2019-05       Impact factor: 0.743

9.  C3 glomerulonephritis with a severe crescentic phenotype.

Authors:  Aishwarya Ravindran; Fernando C Fervenza; Richard J H Smith; Sanjeev Sethi
Journal:  Pediatr Nephrol       Date:  2017-06-07       Impact factor: 3.714

10.  Deletion Variants of CFHR1 and CFHR3 Associate with Mesangial Immune Deposits but Not with Progression of IgA Nephropathy.

Authors:  Perrine Jullien; Blandine Laurent; Guillaume Claisse; Ingrid Masson; Miriana Dinic; Damien Thibaudin; Francois Berthoux; Eric Alamartine; Christophe Mariat; Nicolas Maillard
Journal:  J Am Soc Nephrol       Date:  2017-11-07       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.